It has come to our notice that certain fraudulent individuals or entities are misusing our Company’s name and TCI’s registered trademarks by promoting and offering regulated and hazardous chemical substances through online platforms like YouTube. We hereby categorically clarify that TCI has no association or connection whatsoever with the products being displayed or sold in the videos. These products have been falsely represented as being associated with TCI, and the unauthorized use of our trademark and brand name is both illegal and misleading. TCI Chemicals markets and sells its products exclusively through its official website and authorized distributors. If you become aware of any such fraudulent activity or require clarification, you may reach out to us at: Sales-IN@TCIchemicals.com. Click Here to View the Caution Notice.
Product Document Searching Made Easy by 2D Code! | [Product Highlights] Endogenous Biotin-Blocking Reagent...Maximum quantity allowed is 999
Please select the quantity
CAS RN: 162401-32-3 | Product Number: R0193
Roflumilast
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 250MG |
₹13,100.00
|
Contact Us | 9 |
|
| 1G |
₹24,800.00
|
Contact Us | 23 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0193 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__7H__1__4Cl__2F__2N__2O__3 = 403.21 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 162401-32-3 |
| Reaxys Registry Number | 9802592 |
| PubChem Substance ID | 354334855 |
| Merck Index (14) | 8249 |
| MDL Number | MFCD00938270 |
Specifications
| Appearance | White to Orange to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 97.0 % |
| Melting point | 157.0 to 161.0 °C |
Properties (reference)
| Melting Point | 159 °C |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| Precautionary Statements | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
Related Laws:
| RTECS# | CV3325600 |
Transport Information:
Application
Roflumilast: A Selective Phosphodiesterase 4 (PDE4) Inhibitor.
Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor. The active metabolite, Roflumilast N-oxide [R0217], also acts as a selective PDE4 inhibitor. PDE4 is a key enzyme in the degradation of cyclic adenosine monophosphate (cyclic AMP) [A2381] and is centrally involved in the cytokine production of inflammatory cells. The inhibition of PDE4 activity leads to accumulation of intracellular cyclic AMP. Roflumilast is used for the treatment of chronic obstructive pulmonary disease (COPD). While the precise mechanism of the therapeutic action in COPD is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells. For your reference, [C3395] and [D4505] are synthetic intermediates of roflumilast. (The product is for research purpose only.)
References
- Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
- Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease (a review)
- The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease (a review)
- Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation
- Isolation, synthesis and structure confirmation of the impurity in crude roflumilast product
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.